Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$4.08 USD
-0.13 (-3.09%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $4.09 +0.01 (0.25%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
AUTL 4.08 -0.13(-3.09%)
Will AUTL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AUTL
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
AUTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?
Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
Other News for AUTL
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
AUTL Makes Notable Cross Below Critical Moving Average
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors